Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

686 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
Sung E, Ko M, Won JY, Jo Y, Park E, Kim H, Choi E, Jung UJ, Jeon J, Kim Y, Ahn H, Choi DS, Choi S, Hong Y, Park H, Lee H, Son YG, Park K, Won J, Oh SJ, Lee S, Kim KP, Yoo C, Song HK, Jin HS, Jung J, Park Y. Sung E, et al. Among authors: kim h, kim kp, kim y. Mol Ther. 2022 Aug 3;30(8):2800-2816. doi: 10.1016/j.ymthe.2022.05.003. Epub 2022 May 6. Mol Ther. 2022. PMID: 35526096 Free PMC article.
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Hwang DW, Song KB, Lee JH, Kim SC. Yoo C, et al. Among authors: kim sc, kim kp, kim mh. Oncotarget. 2017 Jul 11;8(28):46337-46347. doi: 10.18632/oncotarget.17940. Oncotarget. 2017. PMID: 28564637 Free PMC article.
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM. Kim BJ, et al. Among authors: kim kp, kim mh. Cancer Chemother Pharmacol. 2017 Jul;80(1):209-215. doi: 10.1007/s00280-017-3353-2. Epub 2017 Jun 8. Cancer Chemother Pharmacol. 2017. PMID: 28597043
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
Yoo C, Han B, Kim HS, Kim KP, Kim D, Jeong JH, Lee JL, Kim TW, Kim JH, Choi DR, Ha HI, Seo J, Chang HM, Ryoo BY, Zang DY. Yoo C, et al. Among authors: kim tw, kim kp, kim d, kim hs, kim jh. Cancer Res Treat. 2018 Oct;50(4):1324-1330. doi: 10.4143/crt.2017.526. Epub 2018 Jan 8. Cancer Res Treat. 2018. PMID: 29334603 Free PMC article. Clinical Trial.
FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment.
Chae H, Yoo C, Yoon JA, Lee HJ, Kim KP, Kim JE, Ahn JH, Jung KH, Gong G, Kim SB. Chae H, et al. Among authors: kim sb, kim kp, kim je. J Breast Cancer. 2018 Mar;21(1):45-50. doi: 10.4048/jbc.2018.21.1.45. Epub 2018 Mar 23. J Breast Cancer. 2018. PMID: 29628983 Free PMC article.
686 results